Log In
Print
BCIQ
Print
Print this Print this
 

IGN786

  Manage Alerts
Collapse Summary General Information
Company Igenica Inc.
DescriptionAntibody-drug conjugate
Molecular Target
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPreclinical
Standard IndicationChronic lymphocytic leukemia (CLL)
Indication DetailsTreat chronic lymphocytic leukemia (CLL)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today